Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

This study has been completed.
Sponsor:
Collaborators:
Synteract, Inc.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Savara Inc.
ClinicalTrials.gov Identifier:
NCT01746095
First received: December 6, 2012
Last updated: December 5, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2014
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)